Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects of dapagliflozin on kidney function, as assessed by glomerular filtration rate.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Astra Zeneca, Bristol-Myers Squibb
• Treatments: Dapagliflozin; Hydrochlorothiazide

Criteria

Inclusion Criteria:

• Type 2 diabetes and inadequate glycemic control, defined as A1C ≥ 6.6 and ≤ 9.5%

• Stable dose of metformin AND/OR a sulfonylurea, for at least 4 weeks prior to the enrollment visit

• Inadequate blood pressure (BP) control, defined as systolic BP (SBP) ≥ 130 and < 165 mmHg, AND/OR diastolic BP (DBP) ≥ 80 and < 105 mmHg

• C-peptide ≥ 0.8 ng/mL

• Estimated GFR by the Modification of Diet in Renal Disease (MDRD) formula > 60 mL/min/1.73m² and < 150 mL/min/1.73m²

• Urine albumin:creatinine ratio (UACR) < 300 mg/g

• BMI ≤ 45.0 kg/m2

Exclusion Criteria:

• Administration of diuretics or other medication approved for the treatment of hypertension (with the exception of either ACEI or ARB), at any dose during the 12 weeks prior to the enrollment visit

• History of adverse reaction to radio-contrast dye

• Allergy or contraindication to use of thiazide diuretics

• Aspartate Aminotransferase (AST) > 3X Upper limit of normal (ULN)

• Alanine aminotransferase (ALT) > 3X ULN

• Serum Total Bilirubin > 1.5X ULN

• Serum Creatinine (Scr) ≥ 1.50 mg/dL (133 μmol/l) for men; SCr ≥ 1.40 mg/dL (124 μmol/l) for women

• Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncologic, endocrine, psychiatric, or rheumatic diseases